Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Julphar
Dow
Teva
Express Scripts
McKesson
Merck
Cerilliant
Fish and Richardson
US Department of Justice

Generated: January 19, 2018

DrugPatentWatch Database Preview

LIFITEGRAST - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lifitegrast and what is the scope of lifitegrast patent protection?

Lifitegrast
is the generic ingredient in one branded drug marketed by Shire Dev Llc and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lifitegrast has ninety-four patent family members in twenty countries.

One supplier is listed for this compound.
Summary for LIFITEGRAST
International Patents:94
US Patents:13
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 9
Clinical Trials: 6
Patent Applications: 48
Drug Prices:see low prices
DailyMed Link:LIFITEGRAST at DailyMed

US Patents and Regulatory Information for LIFITEGRAST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for LIFITEGRAST

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,708,303 LFA-1 inhibitor and methods of preparation and polymorph thereof ➤ Subscribe
8,871,935 Crystalline pharmaceutical and methods of preparation and use thereof ➤ Subscribe
8,378,105 Crystalline pharmaceutical and methods of preparation and use thereof ➤ Subscribe
9,045,457 Compositions and methods for treatment ➤ Subscribe
8,771,715 Compositions and methods for treatment ➤ Subscribe
8,758,776 Compositions and methods for treatment ➤ Subscribe
9,045,458 Compositions and methods for treatment ➤ Subscribe
7,989,626 Modulators of cellular adhesion ➤ Subscribe
9,248,126 Modulators of cellular adhesion ➤ Subscribe
9,051,297 Compositions and methods for treatment ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for LIFITEGRAST

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Teva
Daiichi Sankyo
Chubb
Citi
Express Scripts
Chinese Patent Office
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot